This research provides an overview of T2DM models that were developed between 2008 and January 2013. The outcomes of the qualitative assessments, combined with frequent use in local reimbursement decisions, prove the applicability of the CORE, CARDIFF and UKPDS models to address decision problems related to the long-term clinical and economic consequences of new and existing T2DM treatments.
Ciprofloxacin plus fluocinolone acetonide is a more effective treatment for diffuse otitis externa than ciprofloxacin alone. The ciprofloxacin plus fluocinolone acetonide combination also has an excellent safety profile.
During an 18-month period of study 41 hemodialyzed patients receiving desferrioxamine (10–40 mg/kg BW/3 times weekly) for the first time were monitored for detection of audiovisual toxicity. 6 patients presented clinical symptoms of visual or auditory toxicity. Moreover, detailed ophthalmologic and audiologic studies disclosed abnormalities in 7 more asymptomatic patients. Visual toxicity was of retinal origin and was characterized by a tritan-type dyschromatopsy, sometimes associated with a loss of visual acuity and pigmentary retinal deposits. Auditory toxicity was characterized by a mid- to high-frequency neurosensorial hearing loss and the lesion was of the cochlear type. Desferrioxamine withdrawal resulted in a complete recovery of visual function in 1 patient and partial recovery in 3, and a complete reversal of hearing loss in 3 patients and partial recovery in 3. This toxicity appeared in patients receiving the higher doses of desferrioxamine or coincided with the normalization of ferritin or aluminium serum levels. The data indicate that audiovisual toxicity is not an infrequent complication in hemodialyzed patients receiving desferrioxamine. Periodical audiovisual monitoring should be performed on hemodialyzed patients receiving the drug in order to detect adverse effects as early as possible.
and public oncology centers in Brazil. RESULTS: Treatment was received by 161 eligible patients. The majority of patients were men (54.5%), and 30.3% were first diagnosed at stage IV. Across up to three lines of treatment, 76.4% received systemic therapy, 57.8% had surgery, 37.9% received radiotherapy and 9.3% received supportive care. Among first line treatment, 30.4% received systemic treatment only and 42.2% systemic in combination with surgery and/or radiotherapy. Second line treatment was administered to 67 patients; of those, 88.1% had systemic treatment, 9.0% received surgery, and 10.4% received radiotherapy. Only 26 patients received third line treatment. Outside clinical trial, the most commonly-used drug alone or in combination on first-line was Dacarbazine in both public (82.3%) and private (68.0%) systems, followed by Interferon in the public system (25.8%) and Interleukin in the private system (40.0%). The mean duration of systemic treatment was 17.6 (95% confidence interval (CI) 14.1-21.2) weeks. For second line, the most commonly-used drug was Paclitaxel (31.2%) for private system and Interferon and Paclitaxel (both 24.0%) for public system. Mean systemic treatment duration was 11.8 (95% CI 7.2-16.4) weeks. In third line, Fotemustine and Dacarbazine were the most commonly-used drugs. CONCLUSIONS: In Brazil the most common treatment for unresectable stage III and IV melanoma is systemic treatment combined with surgery and/or radiotherapy. The most comonly used agent in first line is Dacarbazine; most common second line treatments are Paclitaxel and Interferon.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.